Black W D, Acchiardo S R
South Med J. 1977 Oct;70(10):1240-1.
Acetohexamide hypoglycemia in a patient with renal failure has been successfully treated by peritoneal dialysis. Peritoneal dialysis was done in such a patient, and specimens of serum were collected to measure levels of acetohexamide and its main active metabolite, hydroxyhexamide. During dialysis, hypoglycemia was corrected. After 17 1/2 hours of dialysis, serum acetohexamide level was essentially unchanged. Serum hydroxyhexamide level had decreased at a slower rate than the rate of decrease previously measured in a uremic patient not on dialysis. Although peritoneal dialysis may correct the hypoglycemia, the data suggest that acetohexamide and hydroxyhexamide are not dialyzable. Due to these problems this drug should not be used in patients with chronic renal failure. The drug of choice to control hyperglycemia in patients with renal insufficiency is insulin. If for any reason insulin cannot be used, tolbutamide is the oral hypoglycemic agent of choice.
一名肾衰竭患者的醋磺己脲低血糖症已通过腹膜透析成功治疗。对该患者进行了腹膜透析,并采集血清样本以测量醋磺己脲及其主要活性代谢物羟基己脲的水平。透析过程中,低血糖得到纠正。透析17个半小时后,血清醋磺己脲水平基本未变。血清羟基己脲水平下降速度比之前未进行透析的尿毒症患者测得的下降速度慢。虽然腹膜透析可纠正低血糖,但数据表明醋磺己脲和羟基己脲不可透析。由于这些问题,该药物不应在慢性肾衰竭患者中使用。控制肾功能不全患者高血糖的首选药物是胰岛素。如果由于任何原因不能使用胰岛素,甲苯磺丁脲是口服降糖药的首选。